Tardive Dyskinesia (TD) | AUSTEDO XR® (deutetrabenazine) …
AUSTEDO XR ® (deutetrabenazine) extended-release tablets and AUSTEDO ® (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with …
Clinical Studies Results | AUSTEDO (deutetrabenazine)
View the clinical study details for AUSTEDO (deutetrabenazine) tablets and treatment of Tardive Dyskinesia. See safety info and boxed warning.
Teva Pharmaceutical Industries Shares Positive Patient Survey …
Quiver AI Summary Teva Pharmaceuticals has reported positive results from a real-world survey of 209 patients with tardive dyskinesia (TD) who were treated with AUSTEDO XR® …
Study Explores Tardive Dyskinesia Outcomes With …
Nov 12, 2024 · It demonstrates real-world treatment patterns and outcomes with once-daily Austedo XR (deutetrabenazine) extended-release tablets and twice-daily Austedo …
What is the treatment for tardive dyskinesia? - droracle.ai
Jun 14, 2025 · The efficacy of AUSTEDO in the treatment for tardive dyskinesia was established in two 12‑week, randomized, double-blind, placebo-controlled, multi-center trials conducted in …
The safety and effectiveness of Austedo have not been established in pediatric patients for the treatment of chorea associated with Huntington’s disease or for the treatment of tardive …
List of 21 Tardive Dyskinesia Medications Compared - Drugs.com
Mar 5, 2024 · Compare risks and benefits of common medications used for Tardive Dyskinesia. Find the most popular drugs, view ratings and user reviews.
Teva Presents IMPACT-TD Data On Tardive Dyskinesia, Revealing …
Nov 2, 2024 · The IMPACT-TD Registry is the largest study of its kind evaluating the holistic effects of tardive dyskinesia (TD), showing real-world treatment patterns and outcomes with …
Clinical & Real-World Data | Tardive Dyskinesia (TD) | AUSTEDO ...
See the tardive dyskinesia (TD) clinical trial results for AUSTEDO. See Prescribing Information, including Boxed Warning.
Teva Presents Real-World Data for AUSTEDO ... - Teva …
Jun 2, 2023 · The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and …